Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 14/20 | 0.34 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15876012 | 1.00 | CA2 (0.35) | CA2MAPK1CTSKSLC1A3SLC1A2 | |
| SCHEMBL19714607 | 0.87 | CPB2 (0.35) | MEN1GAAKMT2A | |
| SCHEMBL16447368 | 0.86 | — | — | |
| SCHEMBL15880920 | 0.80 | — | — | |
| SCHEMBL31349728 | 0.79 | — | — | |
| SCHEMBL15880919 | 0.79 | — | — | |
| SCHEMBL29696200 | 0.76 | CA2 (0.42) | CA2MAPK1CTSKSLC1A3SLC1A2 | |
| SCHEMBL66398 | 0.76 | CA2 (0.42) | CA2MAPK1CTSKSLC1A3SLC1A2 | |
| SCHEMBL7761798 | 0.76 | CA2 (0.42) | CA2MAPK1CTSKSLC1A3SLC1A2 | |
| SCHEMBL66399 | 0.76 | CA2 (0.42) | CA2MAPK1CTSKSLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014111545-A1 | COMPOUNDS FOR FUNCTIONALIZING BIOMATERIALS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2014-07-24 | — | — | WO | disclosed |
| EP-2757098-A1 | Compounds for Functionalizing Biomaterials | Ecole Polytechnique Fédérale de Lausanne (EPFL) (CH) | 2014-07-23 | — | — | EP | disclosed |
| US-8703907-B2 | Controlled drug release from dendrimers | PROLYNX LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20130123461-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | PROLYNX LLC (US) | 2013-05-16 | — | — | US | disclosed |
| EP-2571496-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | Prolynx Llc (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011140376-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | PROLYNX LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123461-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | SLC43A1, SLC47A1, SLC47A2 | CA2 1296/4885MAPK1 4704/4885CTSK 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.